BioNTech (NASDAQ:BNTX – Get Rating) will be announcing its earnings results before the market opens on Monday, May 9th. Analysts expect the company to announce earnings of $9.84 per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.
BioNTech (NASDAQ:BNTX – Get Rating) last announced its earnings results on Wednesday, March 30th. The company reported $12.18 EPS for the quarter, beating analysts’ consensus estimates of $7.44 by $4.74. The business had revenue of $5.53 billion during the quarter, compared to analysts’ expectations of $3.83 billion. BioNTech had a net margin of 54.20% and a return on equity of 142.70%. The business’s revenue was up 1501.8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.87 earnings per share. On average, analysts expect BioNTech to post $35 EPS for the current fiscal year and $16 EPS for the next fiscal year.
NASDAQ BNTX opened at $138.78 on Monday. The stock has a market capitalization of $34.25 billion, a P/E ratio of 2.97 and a beta of -0.69. BioNTech has a 52-week low of $121.32 and a 52-week high of $464.00. The firm has a 50-day moving average price of $158.10 and a 200 day moving average price of $211.14. The company has a quick ratio of 4.18, a current ratio of 4.33 and a debt-to-equity ratio of 0.01.
The company also recently declared a — dividend, which will be paid on Friday, June 17th. Investors of record on Friday, June 3rd will be issued a dividend of $1.5342 per share. The ex-dividend date is Thursday, June 2nd. This represents a yield of 1.1%.
Several research analysts recently issued reports on BNTX shares. Canaccord Genuity Group cut their price target on shares of BioNTech from $450.00 to $300.00 and set a “buy” rating for the company in a report on Tuesday, April 5th. Morgan Stanley lowered their price target on shares of BioNTech from $217.00 to $197.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 12th. UBS Group decreased their target price on shares of BioNTech from $450.00 to $300.00 and set a “buy” rating on the stock in a research report on Tuesday, April 5th. Redburn Partners raised shares of BioNTech from a “sell” rating to a “neutral” rating in a research note on Tuesday, February 1st. Finally, Zacks Investment Research downgraded shares of BioNTech from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 27th. Eight analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, BioNTech currently has an average rating of “Hold” and an average target price of $259.59.
A number of hedge funds and other institutional investors have recently modified their holdings of BNTX. Geode Capital Management LLC lifted its position in BioNTech by 11.8% during the 4th quarter. Geode Capital Management LLC now owns 65,882 shares of the company’s stock worth $16,984,000 after buying an additional 6,958 shares in the last quarter. State Street Corp lifted its position in BioNTech by 10.7% during the 4th quarter. State Street Corp now owns 57,074 shares of the company’s stock valued at $14,714,000 after purchasing an additional 5,517 shares during the period. Alliancebernstein L.P. acquired a new position in BioNTech during the 4th quarter valued at about $3,867,000. Mackenzie Financial Corp lifted its position in BioNTech by 201.2% during the 4th quarter. Mackenzie Financial Corp now owns 3,199 shares of the company’s stock valued at $825,000 after purchasing an additional 2,137 shares during the period. Finally, Legal & General Group Plc lifted its position in BioNTech by 18.0% during the 4th quarter. Legal & General Group Plc now owns 31,272 shares of the company’s stock valued at $7,623,000 after purchasing an additional 4,769 shares during the period. Institutional investors and hedge funds own 15.13% of the company’s stock.
BioNTech Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.